Clinical trials: PSC
Secondary Sclerosing Cholangitis
Biliary Interventions in Critically Ill Patients With Secondary Sclerosing Cholangitis (BISCIT)
This is a randomized, open-label, controlled, parallel group, multicenter clinical trial. Patients with confirmed secondary sclerosing cholangitis (SSC-CIP) will be randomized either in the intervention group undergoing scheduled…
- Trial name
- BISCIT (NCT05396755)
- Testing
- Endoscopic retrograde cholangiography (ERC)
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- Hannover Medical School
Neuro-PASC, Long COVID
Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans
Mental health symptoms, including cognitive impairment ("brain fog"), following COVID-19 are of great concern to Veterans. This research seeks to advance understanding of the long-term effects of COVID-19 on neuropsychiatric and…
- Trial name
- PASC (NCT06932237)
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- VA Office of Research and Development
Long COVID, Brain Fog
Long COVID Brain Fog: Cognitive Rehabilitation Trial
This study will compare two approaches to cognitive rehabilitation in adults with long COVID with persistent, mild to moderate, cognitive impairment.
- Conditions
- Long COVID, Brain Fog, Cognitive Impairment, Cognitive Dysfunction
- Trial name
- NCT06095297
- Testing
- Processing Speed Training, In-lab Instrumental Activities of Daily Living Training, In-lab Brain Health Training
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
COVID-19
Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
The primary objective of this study is to assess the feasibility and acceptability of methods and procedures to be employed in a larger scale decentralized platform adaptive randomized clinical trial in patients with a history of…
- Trial name
- NCT05946551
- Testing
- Cetirizine, Famotidine
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
CM-101 is developed as treatment for medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC), Systemic Sclerosis (SSc)
- Trial name
- NCT06037577
- Testing
- CM-101
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- ChemomAb Ltd.
Primary Sclerosing Cholangitis
Trial of High-dose Urso in Primary Sclerosing Cholangitis
This is a multicenter, randomized, controlled trial of high dose ursodiol versus placebo for patients with primary sclerosing cholangitis (PSC).
- Trial name
- NCT00059202
- Testing
- Ursodeoxycholic Acid
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Long Covid
Long COVID Ultrasound Trial
The research objective is to assess the safety and potential efficacy of spleen ultrasound stimulation as an intervention for Long COVID in a pilot study.
- Trial name
- LOCUS (NCT06189066)
- Testing
- Splenic Ultrasound
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- SecondWave Systems Inc.
Inflammatory Bowel Diseases, Primary Sclerosing Cholangitis
A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD
Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). Although rare, PSC is associated with significant and disproportionate unmet needs; with heightened risks of…
- Trial name
- PSC-Vanc (NCT05376228)
- Testing
- Oral Vancomycin
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Post-Acute COVID-19 Syndrome
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from an acute COVID-19 infection may continue to have symptoms that persist for months or years.
- Trial name
- NCT07388550
- Testing
- Keytruda
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Post COVID Condition
RECLAIM Adaptive Platform Trial for PCC Treatments
RECLAIM is a Phase III, multi-domain, randomized, controlled, adaptive platform trial, designed to evaluate efficacy and safety of repurposed medications in patients with post-COVID condition (PCC).
- Trial name
- RECLAIM (NCT07280572)
- Testing
- Metformin, colchicine
- Where
- Netherlands
- Volunteers
- 1,250 people
- Sponsor
- Janneke van de Wijgert
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder
Vancomycin in Primary Sclerosing Cholangitis in Italy
Primary sclerosing cholangitis (PSC) is chronic fibroinflammatory disease of the liver. There is still no medical therapy proven to halt the progression of PSC or prevent its serious complications.
- Conditions
- Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder, IBD
- Trial name
- VanC-IT (NCT05876182)
- Testing
- Oral Vancomycin
- Where
- Italy
- Volunteers
- 84 people
- Sponsor
- University of Milano Bicocca
Primary Sclerosing Cholangitis
Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy for PSC Biliary Strictures
Primary sclerosing cholangitis (PSC) 1. Prospectively validate interpretation criteria for the characterization of PSC strictures 2.
- Trial name
- PSCRegistry (NCT02736708)
- Testing
- probe based confocal laser endomicroscopy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Colorado, Denver
Long COVID, Insulin Resistance
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC).
- Conditions
- Long COVID, Insulin Resistance, Insulin Sensitivity
- Trial name
- NCT05833217
- Testing
- Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
- Where
- 2 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Stanford University
Primary Sclerosing Cholangitis, Liver Diseases
Primary Sclerosing Cholangitis in Children
Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine.
- Conditions
- Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
- Trial name
- NCT04181138
- Where
- 12 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Arbor Research Collaborative for Health
Social Anxiety Disorder
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in…
- Trial name
- PALISADE-3 (NCT06358651)
- Testing
- Fasedienol Nasal Spray
- Where
- 24 sites in United States
- Volunteers
- 238 people
- Sponsor
- VistaGen Therapeutics, Inc.
Inflammatory Bowel Disease, Colorectal Cancer
Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease
Build a collection of fecal microbiota in order to determine the characteristics of gut microbiota associated with colorectal cancer in Inflammatory bowel disease (IBD).
- Trial name
- DYSCOLIC (NCT02726243)
- Where
- France
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatobiliary Diseases
Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases
The investigators hypothesize that the extent of sulfation of toxic BAs and their urinary elimination can be used as a biomarker to predict the severity and prognosis of hepatobiliary diseases.
- Trial name
- NCT01200082
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Primary Sclerosing Cholangitis (PSC), Inflammatory Bowel Disease (IBD)
Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation
Primary Sclerosing Cholangitis (PSC) is a rare cholestatic liver disease, commonly associated with inflammatory bowel disease (IBD) The aim of the present trial is to assess the efficacy of fecal microbiota transplantation (FMT)…
- Trial name
- FMT-SCLER (NCT07477782)
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Secondary Sclerosing Cholangitis
Secondary Sclerosing Cholangitis in Critically Ill Patients
SSC-CIP is increasing in patients after critical illness. Pathogenesis is still largely unclear. The investigators hypothesize that genetic variants of biliary transporter genes are frequent in patients with SSC-CIP.
- Trial name
- SSC-CIP (NCT02545309)
- Where
- Austria
- Volunteers
- 140 people
- Sponsor
- Medical University of Graz